Growth factor enriched collagen matrix versus de-epithelialized graft in root coverage procedures - A randomized parallel arm clinical trial Authors: Sanathana Polimera, Anupama Tadepalli, Harinath Parthasarathy, Priyanka K. Cholan, Lakshmi Ramachandran Published: 2026 ABSTRACT AimThis randomized parallel arm single blinded trial, evaluated the clinical efficacies of de epithelialized free gingival graft (DFGG) and volume stable collagen matrix (VCMX) enriched with injectable platelet-rich fibrin (i-PRF) along with coronally advanced flap (CAF) for the treatment of recession defects. The objectives were to assess and compare changes in recession depth (RD) and root coverage percentage (RC) between the groups.Materials and methodsForty-five systemically healthy individuals presenting Cairo's RT1/RT2 recession defects in the maxilla were treated either with control (CAF + DFGG, n = 23) or test intervention (CAF + i-PRF + VCMX, n = 22). Parameters such as recession depth (RD) and keratinized tissue width (KTW) were measured at baseline, 6 and 12 months. Mean and complete root coverage percentages (MRC and CRC) were calculated.ResultsFrom baseline to 12 months, a statistically significant reduction in mean RD was observed in both the treatment groups (p < 0.001). At 12 months, the control group demonstrated a MRC of 90.21 ± 28.93% and CRC of 89.13 ± 29.99% and the test group showed a MRC of 81.62 ± 32.03% with CRC of 72.73 ± 45.58%. Intergroup analysis revealed no statistically significant differences in the measured clinical parameters at 6 and 12 months (p > 0.05).ConclusionWithin the limits of this study, volume-stable xenogeneic collagen matrix enriched with i-PRF resulted in similar outcomes to those achieved with de-epithelialized free gingival graft in the treatment of maxillary gingival recession defects. Introduction The objective of contemporary periodontal plastic surgery is to achieve complete root coverage (CRC) with significant periodontal regeneration. Autogenous gingival grafts are considered as the gold standard protocols for treatment of gingival recession defects because of their predictable long-term outcomes.1 However, their clinical application is often associated with donor site morbidity, extended operative time, patient discomfort, and limited availability of donor tissue. Several alternative biomaterials have been investigated, including autologous platelet concentrates, allogeneic grafts such as acellular dermal matrices, amnion-chorion membranes, pericardial membranes, and native or reconstituted collagen-based membranes/matrices of xenogeneic origin to achieve comparable outcomes as autogenous grafts in management of gingival recession. Systematic reviews and meta-analyses indicated that while these materials provide acceptable clinical outcomes, their effectiveness remains variable, in terms of achieving CRC and increasing gingival thickness (GT).2 Advances in biomaterial research have led to the development of a biodegradable, volume-stable collagen matrix (VCMX), derived from reconstituted porcine tissues. This biomaterial is predominantly composed of type I and III collagen and on hydration, the matrix undergoes volume expansion and maintains dimensional stability for 12 weeks before undergoing gradual resorption over a period of 20-24weeks.3,4 Volume-stable xenogeneic collagen matrices permit angiogenesis, act as scaffolds for fibroblast migration and tissue remodeling. The bio-inert nature of these matrices limits them to function primarily as cell-conductive scaffolds without inductive properties.5 Biofunctionalization of collagen matrices has been proposed to improve regenerative outcomes. In vitro and preclinical studies have demonstrated that scaffolds enriched with platelet-derived growth factors significantly enhanced gingival fibroblast viability, migration, metabolic activity, thereby enhancing wound healing properties.6, 7, 8 Injectable platelet-rich fibrin(i-PRF) serves as an autologous source of growth factors, and has been shown to support soft tissue healing when combined with scaffold materials.9 Limited trials have investigated the application of VCMX supplemented with platelet derived growth factors (rh-PDGF BB or i-PRF) in the treatment of gingival recession.10, 11, 12 Authors reported favorable root coverage outcomes of biofunctionalized VCMX compared to plain VCMX.12 At present, the clinical efficacy of a biofunctionalized xenogeneic volume-stable collagen matrix compared with autogenous gingival grafts in the treatment of gingival recession defects has not been well established. This exploratory comparative research aimed to compare the clinical efficacy of a volume-stable xenogeneic collagen matrix (VCMX) incorporated with injectable platelet-rich fibrin (i-PRF) versus a de-epithelialized gingival graft (DFGG) in the treatment of gingival recession defects. The primary objectives of this research were to compare the changes in recession depth (RD) and number of sites achieving complete root coverage (CRC) between the research groups. The secondary objectives of this research were to assess and compare changes in gingival thickness (GT), as well as patient perceptions of postoperative pain and esthetics. Materials and methods Study design and ethical considerations This prospective, randomized, parallel-arm clinical trial was registered with the Clinical Trials Registry–India (CTRI/2023/08/056045) and approved by the Institutional Ethics Committee and Scientific Review Board of SRM Dental College (SRMDC/IRB/2022/MDS/No.504). The protocol adhered CONSORT guidelines,13 and complied with the ethical principles outlined in the revised Declaration of Helsinki.14 The research was conducted at the Department of Periodontology, SRM Dental College, Chennai, India, between September 2023 and December 2025. Study population and sample size Systemically healthy individuals presenting with gingival recession defects requiring surgical intervention were screened for eligibility. Study outcomes reported by Tavelli L. et al.15 indicated that an estimated sample 42 subjects (21 per group) were required to achieve 80% statistical power at a 5% α level of significance. To compensate for an anticipated dropout rate of approximately 10%, a total of 46 participants were enrolled and equally allocated between the two groups. Eligibility criteria Participants aged between 25 and 55 years, diagnosed with Cairo's16 RT1 or RT2 gingival recession defects involving maxillary anterior or premolar teeth, exhibiting a recession depth ≥ 2 mm, were included. RT2 recession sites were considered only when interproximal attachment loss was < 2 mm, without clinical exposure of proximal cemento-enamel junction. Exclusion criteria included recession affecting more than four adjacent teeth, probing pocket depth ≥ 4 mm, tooth mobility, occlusal trauma, active carious lesions, or prosthetic restorations at the involved sites. Smokers, pregnant or lactating women, individuals with known allergic response to porcine-derived materials were exempted. Subjects with a history of platelet disorders, or receiving medications known to influence platelet function were also excluded. Written informed consent was obtained from all participants prior to enrolment. Randomization and blinding Patients were enrolled by LR. Participants were assigned to treatment groups using Random Allocation Software 2.0 to assign either for test or control intervention. The allocation sequence was generated and maintained by an independent assistant who was not involved in the enrollment, treatment, or assessment processes. Allocation data were preserved using sequentially numbered, opaque, sealed envelopes, which were opened immediately prior to surgery. The trial followed a single-blinded design, where the evaluator assessing the clinical parameters was blinded to the intervention being performed. Documentation of clinical parameters and initial periodontal therapy All clinical measurements were recorded by a single calibrated examiner (SP) who was calibrated before the commencement of the research. Ten adult participants, presenting with a total of 23 gingival recession defects in the maxillary arch, were examined at two distinct intervals, separated by 48 h. The intraclass correlation coefficient (ICC) indicated a high level of intra-examiner reliability, with values of 0.921 (95% CI: 0.82–0.97) for recession depth. In the current study, clinical measurements were standardized using a custom-fabricated acrylic stent with a reference groove and recorded with a UNC-15 periodontal probe. Parameters assessed included recession depth (RD), recession width (RW), probing pocket depth (PPD), clinical attachment level (CAL), and width of keratinized tissue (KTW) at baseline, 6months and 12 months post-surgery. Gingival thickness (GT) was determined using an endodontic reamer. Post-operative pain was recorded at 1, 2, and 4 weeks using a visual analogue scale (VAS-P). Esthetic outcomes were evaluated at 12 months using the root coverage esthetic score (RES) and a visual analogue scale for esthetics (VAS-E). Participants underwent phase I periodontal therapy prior to surgery, consisting of reinforced oral hygiene instructions and full-mouth scaling and root surface debridement using ultrasonic and area specific curettes. Surgical procedure In this research two treatment protocols were used for the management of gingival recession. Test sites (CAF + i-PRF + VCMX), were treated using a coronally advanced flap combined with injectable platelet-rich fibrin enriched volume-stable xenogeneic collagen matrix. Control sites (CAF + DFGG), were intervened with a coronally advanced flap along with a de-epithelialized free gingival graft (Fig. 1). A single periodontist performed all the surgical procedures (AT).Fig. 1CONSORT chart showing the study design, patient recruitment, details of intervention and follow up care. CONSORT chart showing the study design, patient recruitment, details of intervention and follow up care. Under local anesthesia (2% lignocaine, 1:80,000 epinephrine), a trapezoidal flap (Figs. 2b and 3b) was elevated using the split–full–split thickness technique as described by De Sanctis (2007).17 Root surface debridement and papillary de-epithelialization were performed, and flap mobility was assessed to ensure tension-free coronal advancement (see Fig. 4).Fig. 2Control group (CAF + DFGG)Fig. 2a. Baseline, 2b. flap outline, 2c. flap elevation, 2d. de epithelialized free gingival graft, 2e. adaptation of DFGG on root surface, 2f. flap closure, 2g. suture removal, 2h. 12 months post-surgery.Fig. 3Test group (CAF + i-PRF + VCMX)Fig. 3a. Baseline, 3b. flap outline, 3c. flap elevation, 3d. bio functionalization of volume stable collagen matrix using injectable platelet rich fibrin, 3e. adaptation of biofunctionalized VCMX on root surface, 3f. flap closure, 3g. suture removal, 3h. 12 months post-surgery. Control group (CAF + DFGG) Fig. 2a. Baseline, 2b. flap outline, 2c. flap elevation, 2d. de epithelialized free gingival graft, 2e. adaptation of DFGG on root surface, 2f. flap closure, 2g. suture removal, 2h. 12 months post-surgery. Test group (CAF + i-PRF + VCMX) Fig. 3a. Baseline, 3b. flap outline, 3c. flap elevation, 3d. bio functionalization of volume stable collagen matrix using injectable platelet rich fibrin, 3e. adaptation of biofunctionalized VCMX on root surface, 3f. flap closure, 3g. suture removal, 3h. 12 months post-surgery. In the control group, the palatal vault thickness at the donor site was measured prior to graft harvest to confirm a baseline minimum thickness of 2 mm. A free gingival graft (DFGG), matching the dimensions of the recipient site and maintaining a uniform thickness of 1.0–1.5 mm, was harvested using the Zucchelli technique (2010).18 Following de-epithelialization (Fig. 2d) and the removal of residual adipose tissue, the graft was positioned over the exposed root surface extending to the cementoenamel junction (CEJ). (Fig. 2e). The flap was coronally positioned to the level of, or slightly coronal to, the CEJ and stabilized using 4-0 resorbable sling sutures (Vicryl*). Vertical releasing incisions were closed with interrupted sutures, and the donor site was approximated using cross-mattress sutures (Fig. 2f). The injectable platelet-rich fibrin (i-PRF) was prepared following the protocol established by Mourao et al. (2015).19 Approximately 10 ml of intravenous blood was collected via venipuncture from the antecubital fossa, specifically from either the median cubital or median cephalic veins. The collected blood was immediately transferred into sterile vacutainers specified by the manufacturer (Vacutech® yellow tubes) and subjected to centrifugation according to the manufacturer's instructions for i-PRF preparation. This involved centrifugation at 700 RPM for 4 min using a low-speed centrifuge (Labtech LD-C10 Dentifuge®) equipped with a 330 fixed angled rotor with a radius of approximately 8 cm. Post-centrifugation, the upper liquid layer, enriched with platelets and leukocytes (i-PRF) and located near the buffy coat interface, was carefully retrieved using a sterile disposable syringe. A 3-mm-thick xenogeneic VCMX (Fibro-Gide®) was trimmed to the recipient site dimensions and biofunctionalized by immersion in i-PRF for 15 min (Fig. 3d).20 The matrix was positioned over the recipient site, and the flap was coronally advanced and stabilized using the similar suturing (Vicryl*) protocol as in the control group (Fig. 3f). A periodontal dressing (Coe-Pak™) was placed on the surgical area in both groups. Postoperative care and follow-up All participants received amoxicillin (500 mg, three times daily for five days) and analgesics as required. Mechanical plaque control in the surgical sites was avoided for four weeks, and a 0.12% chlorhexidine mouth rinse was prescribed twice daily. Sutures were removed after two weeks (Figs.. 2g and 3g). Patients were reviewed at 1, 6, and 12 months post-surgery. Healing was uneventful in both groups. A CONSORT flow diagram illustrating participant enrollment, allocation, intervention, and analysis is presented in Fig. 1. Statistical analysis Statistical analysis was carried out using SPSS software (IBM SPSS Statistics, Version 23.0; IBM Corp., Armonk, NY, USA). Continuous variables were expressed as mean and standard deviation. Categorical variables were summarized as frequencies and percentages. In the present study, the patient was considered as the unit of analysis. For participants presenting with a isolated gingival recession defect, clinical measurements at that specific site were taken as representative values of the patient. In participants who had multiple adjacent gingival recession defects, continuous clinical parameters were averaged across sites to obtain a single subject-level value for statistical analysis. For the categorical outcome of complete root coverage (CRC), a subject-level measure was similarly calculated as the percentage of treated sites per patient achieving CRC, in addition to the site-level frequency reported descriptively. Data normality was assessed using the Kolmogorov–Smirnov test, which indicated a non-parametric distribution of the study variables. Intergroup comparisons of continuous variables including subject-level percentage of sites achieving CRC were assessed using the Mann–Whitney U test. Significant differences with regard to categoric variables were analyzed using Chi-square test or Fisher's exact test. Intragroup comparisons across different time points were done using the Friedman test, followed by the Wilcoxon signed-rank test for continuous variables. Effect size for RD, MRC and CRC parameters were calculated using the rank-biserial correlation to quantify the magnitude of the treatment effect. A p-value < 0.05 was considered statistically significant for all analyses. Results A total of 46 systemically healthy adults manifesting 65 Cairo RT1 and RT2 maxillary gingival recession defects were treated using a CAF + i-PRF + VCMX (n = 23) combination or CAF + DFGG (n = 23) intervention. One participant in the test group discontinued follow-up at the 6-month review due to medical reasons. At the 12-month evaluation, data analysis included 22 subjects in the test group and 23 subjects in the control group. Baseline analysis demonstrated no statistically significant differences between the study groups with respect to demographic parameters, recession site characteristics, or mean values of clinical variables (p > 0.05, Table 1).Table 1Demographic details of the study participants, recession site characteristics and mean clinical parameters at baseline.Table 1Descriptive parametersControl group (CAF + DFGG)Test group (CAF + i - PRF + VCMX)p valueMann Whitney U testAge (yr)38.52 ± 10.6940.23 ± 10.640.554Fisher's exact testGenderMale17 (73.9%)19 (86.4%)0.459Female6 (26.1%)3 (13.6%)Chi square testCairo's class of gingival recessionRT110 (31.3%)11 (34.4%)0.79RT222 (68.8%)21 (65.6%)Fisher's exact testTeeth involved in gingival recessionLaterals3 (9.4%)2 (6.3%)0.781Canines15 (46.9%)13 (40.6%)1st Premolar10 (31.3%)14 (43.8%)2nd Premolar4 (12.5%)3 (9.4%)No. of isolated/multiple adjoining sites involved with gingival recessionIsolated/Single15 (65.2%)13 (59.1%)0.874Adjoining two sites7 (30.4%)8 (36.4%)Adjoining three sites1 (4.3%)1 (4.5%)Mann Whitney U testClinical parametersMean ± S.D95% CIMean ± S.D95% CIp valueLowerUpperLowerUpperRecession depth2.47 ± 0.832.1382.8182.48 ± 0.562.2482.7220.89Recession width3.66 ± 0.633.4073.9273.68 ± 0.583.4363.9280.96Gingival thickness1.10 ± 0.231.0061.1981.02 ± 0.150.9631.0910.52Probing pocket depth1.39 ± 0.491.1871.5951.36 ± 0.411.1911.5370.99Clinical attachment level3.87 ± 0.933.4894.2513.84 ± 0.583.6054.0910.82Keratinized tissue width3.21 ± 0.702.9293.5053.08 ± 0.692.7923.3740.81Relative vestibular depth20.50 ± 3.5019.07621.93820.40 ± 2.1019.53121.2870.37CAF + DFGG: coronally advanced flap along with de epithelialized free gingival graft and CAF + i - PRF + VCMX: coronally advanced flap along with volume stable collagen matrix enriched with injectable platelet-rich fibrin, ** denotes p value ≤ 0.001 and * denotes p value ≤ 0.05. Table 1Demographic details of the study participants, recession site characteristics and mean clinical parameters at baseline.Table 1Descriptive parametersControl group (CAF + DFGG)Test group (CAF + i - PRF + VCMX)p valueMann Whitney U testAge (yr)38.52 ± 10.6940.23 ± 10.640.554Fisher's exact testGenderMale17 (73.9%)19 (86.4%)0.459Female6 (26.1%)3 (13.6%)Chi square testCairo's class of gingival recessionRT110 (31.3%)11 (34.4%)0.79RT222 (68.8%)21 (65.6%)Fisher's exact testTeeth involved in gingival recessionLaterals3 (9.4%)2 (6.3%)0.781Canines15 (46.9%)13 (40.6%)1st Premolar10 (31.3%)14 (43.8%)2nd Premolar4 (12.5%)3 (9.4%)No. of isolated/multiple adjoining sites involved with gingival recessionIsolated/Single15 (65.2%)13 (59.1%)0.874Adjoining two sites7 (30.4%)8 (36.4%)Adjoining three sites1 (4.3%)1 (4.5%)Mann Whitney U testClinical parametersMean ± S.D95% CIMean ± S.D95% CIp valueLowerUpperLowerUpperRecession depth2.47 ± 0.832.1382.8182.48 ± 0.562.2482.7220.89Recession width3.66 ± 0.633.4073.9273.68 ± 0.583.4363.9280.96Gingival thickness1.10 ± 0.231.0061.1981.02 ± 0.150.9631.0910.52Probing pocket depth1.39 ± 0.491.1871.5951.36 ± 0.411.1911.5370.99Clinical attachment level3.87 ± 0.933.4894.2513.84 ± 0.583.6054.0910.82Keratinized tissue width3.21 ± 0.702.9293.5053.08 ± 0.692.7923.3740.81Relative vestibular depth20.50 ± 3.5019.07621.93820.40 ± 2.1019.53121.2870.37CAF + DFGG: coronally advanced flap along with de epithelialized free gingival graft and CAF + i - PRF + VCMX: coronally advanced flap along with volume stable collagen matrix enriched with injectable platelet-rich fibrin, ** denotes p value ≤ 0.001 and * denotes p value ≤ 0.05. Demographic details of the study participants, recession site characteristics and mean clinical parameters at baseline. CAF + DFGG: coronally advanced flap along with de epithelialized free gingival graft and CAF + i - PRF + VCMX: coronally advanced flap along with volume stable collagen matrix enriched with injectable platelet-rich fibrin, ** denotes p value ≤ 0.001 and * denotes p value ≤ 0.05. Recession depth and root coverage Both treatment modalities demonstrated a statistically significant reduction in RD from baseline to 6 and 12 months within each group (p < 0.001, Table 2, Fig. 4). Mean RD decreased from 2.47 ± 0.83 mm at baseline to 0.19 ± 0.57 mm at 12 months in the control group, and from 2.48 ± 0.56 mm to 0.46 ± 0.86 mm in the test group. At 12 months, CRC was observed in 28 of 32 sites (87.5%) in the control group and 24 of 32 sites (75%) in the test group. At the subject level, the mean percentage of treated sites achieving CRC per patient was 89.13% (95% CI: 76.1–100.0%) in the control group and 72.73% (95% CI: 54.6–90.9%) in the test group. Mean root coverage (MRC%) at 12 months was 90.21 ± 28.93% in the control group and 81.62 ± 32.03% in the test group.Table 2Inter and intra group analysis of primary objectives.Table 2Inter group analysisClinical parametersControl group (CAF + DFGG)Test group (CAF + i - PRF + VCMX)Mann Whitney U testMean ± S.D95% CIMean ± S.D95% CILowerUpperLowerUpperp valueRecession depthBaseline2.47 ± 0.832.1382.8182.48 ± 0.562.2482.7220.896 months0.15 ± 0.46−0.0370.3410.46 ± 0.860.1290.8930.19912 months0.19 ± 0.57−0.0410.4330.46 ± 0.860.1290.8930.242Mean root coverage percentage (%)6 months92.39 ± 23.1582.9210081.62 ± 32.0368.2495.020.21112 months90.21 ± 28.9378.3910081.62 ± 32.0368.2495.020.269Complete root coverage percentage (%)6 months89.13 ± 29.9976.110072.73 ± 45.5854.690.90.20812 months89.13 ± 29.9976.110072.73 ± 45.5854.690.90.208Intra group analysis - Friedman test followed by Wilcoxon signed Rank testRecession depthControl group (CAF + DFGG)p valueTest group (CAF + i - PRF + VCMX)p valueBaseline to 6months< 0.001**Baseline to 6months< 0.001**Baseline to 12 months< 0.001**Baseline to 12 months< 0.001**CAF + DFGG: coronally advanced flap along with de epithelialized free gingival graft and CAF + i - PRF + VCMX: coronally advanced flap along with volume stable collagen matrix enriched with injectable platelet-rich fibrin, ** denotes p value ≤ 0.001 and * denotes p value ≤ 0.05.Fig. 4Inter and intra group variation of recession depthControl: Coronally advanced flap along with de epithelialized free gingival graft and Test: Coronally advanced flap along with volume stable collagen matrix enriched with injectable platelet-rich fibrin. Table 2Inter and intra group analysis of primary objectives.Table 2Inter group analysisClinical parametersControl group (CAF + DFGG)Test group (CAF + i - PRF + VCMX)Mann Whitney U testMean ± S.D95% CIMean ± S.D95% CILowerUpperLowerUpperp valueRecession depthBaseline2.47 ± 0.832.1382.8182.48 ± 0.562.2482.7220.896 months0.15 ± 0.46−0.0370.3410.46 ± 0.860.1290.8930.19912 months0.19 ± 0.57−0.0410.4330.46 ± 0.860.1290.8930.242Mean root coverage percentage (%)6 months92.39 ± 23.1582.9210081.62 ± 32.0368.2495.020.21112 months90.21 ± 28.9378.3910081.62 ± 32.0368.2495.020.269Complete root coverage percentage (%)6 months89.13 ± 29.9976.110072.73 ± 45.5854.690.90.20812 months89.13 ± 29.9976.110072.73 ± 45.5854.690.90.208Intra group analysis - Friedman test followed by Wilcoxon signed Rank testRecession depthControl group (CAF + DFGG)p valueTest group (CAF + i - PRF + VCMX)p valueBaseline to 6months< 0.001**Baseline to 6months< 0.001**Baseline to 12 months< 0.001**Baseline to 12 months< 0.001**CAF + DFGG: coronally advanced flap along with de epithelialized free gingival graft and CAF + i - PRF + VCMX: coronally advanced flap along with volume stable collagen matrix enriched with injectable platelet-rich fibrin, ** denotes p value ≤ 0.001 and * denotes p value ≤ 0.05. Inter and intra group analysis of primary objectives. CAF + DFGG: coronally advanced flap along with de epithelialized free gingival graft and CAF + i - PRF + VCMX: coronally advanced flap along with volume stable collagen matrix enriched with injectable platelet-rich fibrin, ** denotes p value ≤ 0.001 and * denotes p value ≤ 0.05. Inter and intra group variation of recession depth Control: Coronally advanced flap along with de epithelialized free gingival graft and Test: Coronally advanced flap along with volume stable collagen matrix enriched with injectable platelet-rich fibrin. Intergroup comparisons at the subject level revealed no statistically significant differences between groups for RD (6 months: p = 0.199, r = 0.160; 12 months: p = 0.242, r = 0.146), CRC (p = 0.208, r = 0.154 at both timepoints), or MRC (6 months: p = 0.211, r = 0.158; 12 months: p = 0.269, r = 0.134). Effect sizes (rank-biserial correlation) were uniformly small across all three parameters and both timepoints, consistent with the absence of statistically significant intergroup differences. Gingival thickness The mean GT at both the control and test sites increased significantly from baseline values of 1.10 ± 0.23 mm and 1.02 ± 0.15 mm to 2.03 ± 0.24 mm and 2.02 ± 0.26 mm after 12 months, respectively (p < 0.001). No significant intergroup differences were detected at any evaluation interval (p > 0.05, Table 3).Table 3Inter and intra group analysis of secondary objectives.Table 3Inter group analysisClinical parametersControl group (CAF + DFGG)Test group (CAF + i - PRF + VCMX)Mann Whitney U testMean ± S.D95% CIMean ± S.D95% CILowerUpperLower95% CIp valueGingival thicknessBaseline1.10 ± 0.231.0061.1981.02 ± 0.150.9631.0910.5212 months2.03 ± 0.241.9392.1392.02 ± 0.261.9102.1300.184Visual analogue scale-PainImmediate8.10 ± 1.367.5428.6604.81 ± 2.133.9285.7080.001**1 week6.01 ± 1.465.4146.6143.54 ± 1.223.0344.0560.001**2 weeks4.29 ± 0.863.9454.6491.10 ± 0.970.6991.5130.001**4 weeks0.52 ± 0.890.1550.8890.27 ± 0.700.5670.302Root coverage esthetic score12 months9.02 ± 1.668.3409.7048.86 ± 1.858.0879.6410.614Visual analogue scale-Esthetics12 months8.97 ± 1.698.2859.6718.72 ± 2.167.8239.6310.898Intra group analysis - Friedman test followed by Wilcoxon signed Rank testGingival thicknessControl group (CAF + DFGG)p valueTest group (CAF + i - PRF + VCMX)p valueBaseline to 6months< 0.001**Baseline to 6months< 0.001**Baseline to 12 months< 0.001**Baseline to 12 months< 0.001**CAF + DFGG: coronally advanced flap along with de epithelialized free gingival graft and CAF + i - PRF + VCMX: coronally advanced flap along with volume stable collagen matrix enriched with injectable platelet-rich fibrin, ** denotes p value ≤ 0.001 and * denotes p value ≤ 0.05. Table 3Inter and intra group analysis of secondary objectives.Table 3Inter group analysisClinical parametersControl group (CAF + DFGG)Test group (CAF + i - PRF + VCMX)Mann Whitney U testMean ± S.D95% CIMean ± S.D95% CILowerUpperLower95% CIp valueGingival thicknessBaseline1.10 ± 0.231.0061.1981.02 ± 0.150.9631.0910.5212 months2.03 ± 0.241.9392.1392.02 ± 0.261.9102.1300.184Visual analogue scale-PainImmediate8.10 ± 1.367.5428.6604.81 ± 2.133.9285.7080.001**1 week6.01 ± 1.465.4146.6143.54 ± 1.223.0344.0560.001**2 weeks4.29 ± 0.863.9454.6491.10 ± 0.970.6991.5130.001**4 weeks0.52 ± 0.890.1550.8890.27 ± 0.700.5670.302Root coverage esthetic score12 months9.02 ± 1.668.3409.7048.86 ± 1.858.0879.6410.614Visual analogue scale-Esthetics12 months8.97 ± 1.698.2859.6718.72 ± 2.167.8239.6310.898Intra group analysis - Friedman test followed by Wilcoxon signed Rank testGingival thicknessControl group (CAF + DFGG)p valueTest group (CAF + i - PRF + VCMX)p valueBaseline to 6months< 0.001**Baseline to 6months< 0.001**Baseline to 12 months< 0.001**Baseline to 12 months< 0.001**CAF + DFGG: coronally advanced flap along with de epithelialized free gingival graft and CAF + i - PRF + VCMX: coronally advanced flap along with volume stable collagen matrix enriched with injectable platelet-rich fibrin, ** denotes p value ≤ 0.001 and * denotes p value ≤ 0.05. Inter and intra group analysis of secondary objectives. CAF + DFGG: coronally advanced flap along with de epithelialized free gingival graft and CAF + i - PRF + VCMX: coronally advanced flap along with volume stable collagen matrix enriched with injectable platelet-rich fibrin, ** denotes p value ≤ 0.001 and * denotes p value ≤ 0.05. Patient-reported outcomes Participants in the control group reported significantly higher postoperative pain scores (VAS-P) at immediate, 1-week, and 2-week intervals compared with the test group (p < 0.001). No statistically significant differences in VAS-P scores were observed between groups at 4 weeks post-surgery. At 12 months, esthetic satisfaction scores (VAS-E) were comparable between groups (p > 0.05) (Table 3). Other clinical parameters Inter and intra group variation of clinical parameters, including RW, PPD, CAL, KTW, RVD and RES scores, were presented in Table 3 and Table 4.Table 4Inter and intra group comparison of other clinical parameters.Table 4Inter group analysisClinical parametersControl group (CAF + DFGG)Test group (CAF + i - PRF + VCMX)Mann Whitney U testMean ± S.D95% CIMean ± S.D95% CILowerUpperLower95% CIp valueRecession widthBaseline3.66 ± 0.633.4073.9273.68 ± 0.583.4363.9280.966 months0.32 ± 0.94−0.0620.7141.00 ± 1.710.2821.7180.18212 months0.32 ± 0.94−0.0620.7141.00 ± 1.710.2821.7180.182Probing pocket depthBaseline1.39 ± 0.491.1871.5951.36 ± 0.411.1911.5370.996 months1.19 ± 0.391.0361.3561.20 ± 0.361.0521.3580.77412 months1.15 ± 0.400.9871.3171.20 ± 0.361.0521.3580.306Clinical attachment levelBaseline3.87 ± 0.933.4894.2513.84 ± 0.583.6054.0910.826 months1.30 ± 0.651.0371.5711.67 ± 0.911.2121.9920.18512 months1.30 ± 0.740.9991.6091.67 ± 0.911.2882.0980.092Keratinized tissue widthBaseline3.21 ± 0.702.9293.5053.08 ± 0.692.7923.3740.816 months4.17 ± 0.553.9474.4014.28 ± 0.823.9434.6330.45212 months4.06 ± 0.753.7564.3744.28 ± 0.823.9434.6330.324Relative vestibular depthBaseline20.50 ± 3.5019.07621.93820.40 ± 2.1019.53121.2870.376 months18.84 ± 2.7217.73519.96118.54 ± 2.2417.60919.4810.29312 months18.39 ± 3.1317.10919.67318.52 ± 2.2517.58119.4650.45Intra group analysis - Friedman test followed by Wilcoxon signed Rank testParameterControl group (CAF + DFGG)p valueTest group (CAF + i - PRF + VCMX)p valueRecession widthBaseline to 6months< 0.001**Baseline to 6months< 0.001**Baseline to 12 months< 0.001**Baseline to 12 months< 0.001**Probing pocket depthBaseline to 6months0.086Baseline to 6months0.14Baseline to 12 months0.039*Baseline to 12 months0.14Clinical attachment levelBaseline to 6months< 0.001**Baseline to 6months< 0.001**Baseline to 12 months< 0.001**Baseline to 12 months< 0.001**Keratinized tissue widthBaseline to 6months< 0.001**Baseline to 6months< 0.001**Baseline to 12 months0.001**Baseline to 12 months< 0.001**Relative vestibular depthBaseline to 6months< 0.001**Baseline to 6months< 0.001**Baseline to 12 months< 0.001**Baseline to 12 months< 0.001**CAF + DFGG: coronally advanced flap along with de epithelialized free gingival graft and CAF + i - PRF + VCMX: coronally advanced flap along with volume stable collagen matrix enriched with injectable platelet-rich fibrin, ** denotes p value ≤ 0.001 and * denotes p value ≤ 0.05. Table 4Inter and intra group comparison of other clinical parameters.Table 4Inter group analysisClinical parametersControl group (CAF + DFGG)Test group (CAF + i - PRF + VCMX)Mann Whitney U testMean ± S.D95% CIMean ± S.D95% CILowerUpperLower95% CIp valueRecession widthBaseline3.66 ± 0.633.4073.9273.68 ± 0.583.4363.9280.966 months0.32 ± 0.94−0.0620.7141.00 ± 1.710.2821.7180.18212 months0.32 ± 0.94−0.0620.7141.00 ± 1.710.2821.7180.182Probing pocket depthBaseline1.39 ± 0.491.1871.5951.36 ± 0.411.1911.5370.996 months1.19 ± 0.391.0361.3561.20 ± 0.361.0521.3580.77412 months1.15 ± 0.400.9871.3171.20 ± 0.361.0521.3580.306Clinical attachment levelBaseline3.87 ± 0.933.4894.2513.84 ± 0.583.6054.0910.826 months1.30 ± 0.651.0371.5711.67 ± 0.911.2121.9920.18512 months1.30 ± 0.740.9991.6091.67 ± 0.911.2882.0980.092Keratinized tissue widthBaseline3.21 ± 0.702.9293.5053.08 ± 0.692.7923.3740.816 months4.17 ± 0.553.9474.4014.28 ± 0.823.9434.6330.45212 months4.06 ± 0.753.7564.3744.28 ± 0.823.9434.6330.324Relative vestibular depthBaseline20.50 ± 3.5019.07621.93820.40 ± 2.1019.53121.2870.376 months18.84 ± 2.7217.73519.96118.54 ± 2.2417.60919.4810.29312 months18.39 ± 3.1317.10919.67318.52 ± 2.2517.58119.4650.45Intra group analysis - Friedman test followed by Wilcoxon signed Rank testParameterControl group (CAF + DFGG)p valueTest group (CAF + i - PRF + VCMX)p valueRecession widthBaseline to 6months< 0.001**Baseline to 6months< 0.001**Baseline to 12 months< 0.001**Baseline to 12 months< 0.001**Probing pocket depthBaseline to 6months0.086Baseline to 6months0.14Baseline to 12 months0.039*Baseline to 12 months0.14Clinical attachment levelBaseline to 6months< 0.001**Baseline to 6months< 0.001**Baseline to 12 months< 0.001**Baseline to 12 months< 0.001**Keratinized tissue widthBaseline to 6months< 0.001**Baseline to 6months< 0.001**Baseline to 12 months0.001**Baseline to 12 months< 0.001**Relative vestibular depthBaseline to 6months< 0.001**Baseline to 6months< 0.001**Baseline to 12 months< 0.001**Baseline to 12 months< 0.001**CAF + DFGG: coronally advanced flap along with de epithelialized free gingival graft and CAF + i - PRF + VCMX: coronally advanced flap along with volume stable collagen matrix enriched with injectable platelet-rich fibrin, ** denotes p value ≤ 0.001 and * denotes p value ≤ 0.05. Inter and intra group comparison of other clinical parameters. CAF + DFGG: coronally advanced flap along with de epithelialized free gingival graft and CAF + i - PRF + VCMX: coronally advanced flap along with volume stable collagen matrix enriched with injectable platelet-rich fibrin, ** denotes p value ≤ 0.001 and * denotes p value ≤ 0.05. Discussion Collagen constitutes a major structural component of the extracellular matrix and plays an important role in periodontal wound healing. Volume stable collagen matrices are designed to maintain structural integrity during the healing phase and thereby preserving space for tissue regeneration.21 Al-Maawi et al.7 and Imber et al.8 have demonstrated that biofunctionalization of volumetric collagen matrices with injectable platelet-rich fibrin (i-PRF) enhanced cellular adhesion, proliferation, migration, angiogenesis, and early vascularization compared with the native porcine collagen matrices. Biofunctionalized volume stable xenogeneic collagen matrices have been examined in the literature to enhance gingival and peri-implant mucosal phenotypes. Tavelli L. et al. evaluated the adjunctive use of a XCM with (rh-PDGF) and observed a significant reduction in mean recession depth from 2.87 ± 0.78 mm to 0.33 ± 0.49 mm, associated with a MRC of 88.25% and CRC of 59.57% at 6 months.22 The authors noted a significant increase in mean GT from 0.92 ± 0.26 mm to 1.67 ± 0.31 mm during the study period. The authors reported reduction in MRC of 7.5%, with over 90% of treated sites maintaining a stable gingival margin (≤0.5 mm shift) at 3yrs follow-up.23 Santamaria et al. assessed the use of a VCMX biofunctionalized with i-PRF in combination with a CAF and reported a RD reduction of 4 mm gain in GT of 1 mm at 6 months post-surgery.9 Barootchi S et al. reported 100% CRC in two case reports using rhPDGF-BB enriched collagen matrix at 18 months post-operatively.23 Rossato A. et al. utilized VCMX in conjunction with i-PRF, observing a mean RD reduction from 2.65 ± 0.47 mm to 0.50 ± 0.47 mm with an MRC of 81.13%, 40% CRC and 0.64 ± 0.26 mm gain in GT at 6 months follow up period (p = 0.005).20 Michels R. et al. documented a case report using VCMX combined with i-PRF and reported a significant reduction in RD of 2.87 mm over a 12-month period, achieving a MRC of 83%.10 Subsequently, the authors evaluated this combination efficacy, in an independent clinical trial for treatment of multiple gingival recessions demonstrating a mean reduction in RD of 1.7 mm, MRC% of 53.76%, 0.27 mm gain in GT at the 6 months.11 The reduction in RD and MRC (81.62 ± 32.03%) observed in the test group of the present study is consistent with the findings of the above-mentioned clinical trials. Twenty-four treated sites (75%) and 72.73% of subjects in the test group had attained CRC of at 12 months; the lower CRC values reported by Tavelli et al.22 and Rossato A. et al.20 compared with the present study may be attributed to the inclusion of mandibular gingival recession defects in their study populations. Santamaria et al.12 reported a significant increase in gingival thickness when using i-PRF-biofunctionalized VCMX compared to plain VCMX. Gain in the mean gingival thickness noted in the current research test group is consistent with the observations reported by the previous researchers. The clinical efficacy of de-epithelialized free gingival grafts (DFGG) in treating gingival recession is relatively well-established. Tavelli L et al. analyzed 10 randomized controlled trials (RCTs) and reported that CAF and DFGG combination resulted in a mean RD reduction of 3.43 mm (95% CI: 3.1 to 3.74 mm) at 1 year and 3.06 mm at 5 years' follow-up.24 The authors reported a gain in the mean KTW of 1.92 mm and 1.71 mm at 1-year and 5-year follow-up, in DFGG groups. The results observed in our control group align with the RCTs analyzed in the aforementioned meta-analysis. In the current study, the control group showed a MRC% of 90.21 ± 28.9% at 12 months, whereas Tavelli L et al.24 reported a pooled mean MRC% of 94.0% and 97.14% at 1-year and 5-year follow-up, respectively. Further the reduction in RD, gain in GT, improvement in KTW and MRC% obtained in our control group has aligned with outcomes reported by RCTs analyzed in the above-mentioned meta-analysis.24 Conflicting evidence reported regarding keratinized tissue width (KTW) following the use of enriched xenogeneic collagen matrix (VCMX). Studies by Michels R et al.11 and Tavelli L et al. showed a non-significant increase in mean keratinized tissue width (p > 0.05).22 Conversely, Rossato A. et al.20 and the present study group demonstrated significant improvement in KTW (p < 0.05). The inconsistent outcomes documented with earlier studies may be attributed to the relative smaller sample size. Autografts possess biological advantage, by having inherent genetic determinants that influence the keratinization of the overlying epithelium. Collagen matrices lack these intrinsic cues to direct epithelial phenotype. The current research findings suggest that, biofunctionalization strategies may enhance the biologic behavior of these matrices, potentially promoting the transformation toward a keratinized mucosal phenotype. This hypothesis warrants further histological or molecular analyses to understand the underlying mechanisms influencing KTW outcomes. Significantly higher VAS-P scores were noted in the control group of the present study at immediate, 1 wk and 2 wk post-surgery visits indicating higher pain and discomfort compared to the test group. This observation aligns with the meta-analysis by Cairo et al., where the authors highlighted increased morbidity associated with connective tissue graft groups compared to individuals treated with XCM reporting reduced postoperative discomfort.25 The mean visual analogue scale - esthetics (VAS -E) scores reported by our test group (8.72 ± 2.16), is slightly lower than that of reported by Rossato A et al. (9.4 ± 1.26) at 6 months.20 This discrepancy may be attributed to the variation in individual esthetic perception. The mean RES scores obtained our test group are consistent with the outcomes documented by Barootchi S et al. (9.13 ± 0.64) and Tavelli L et al. (8.17 ± 1.99) in their rhPDGF enriched VCMX groups.15,23 Tavelli L et al.,24 suggested that DFGG, characterized by dense connective tissue composition, exhibits reduced graft shrinkage and demonstrated superior clinical outcomes compared to conventional CTG. Ripoll S et al.26 reported delayed complications following DFGG and categorized them as major (formation of epithelial bands or cysts, cul-de-sac formation, and bone exostoses) and minor complications (pale appearance or change in the color of the grafted area and superficial revascularization).26 In our control group, six out of thirty-two treated sites (18.75%), that had achieved CRC, presented with localized pale and firm mucosa. Ripoll et al. reported similar clinical presentations (46.9% of treated sites) following CAF + DFGG intervention, and observed that this pale firm tissue tends to harmonize with the surrounding area after 12 months.26 To summarize, both interventions resulted in significant improvement in all the studied parameters (RD, RW, GT, KTW and CAL; p < 0.05). The mean root coverage percentage achieved (MRC and CRC) and esthetic scores (VAS-E and RES) were similar between the groups (p > 0.05). Though the intergroup differences did not reach statistical significance, control group demonstrated approximately 9% greater mean root coverage (MRC) and a 14–16% higher proportion of complete root coverage (CRC) than the test group at the 12-month follow-up. These numerical differences may be clinically relevant, as complete root coverage is an important therapeutic endpoint in periodontal plastic surgery and is associated with improved esthetic outcomes, reduced dentinal hypersensitivity, and long-term stability of the gingival margin. Conversely, substantial advantage offered by the enriched collagen matrix protocol was the potential to avoid the need for a second surgical site, thereby minimizing patient discomfort and morbidity, as indicated by the lower VAS-P scores. While interpreting the current research outcomes, it is essential to consider certain methodological limitations despite the use of subject-level analyses. The potential clustering effects from multiple recession defects within individual patients could not be entirely excluded. Additionally, the study's single-center design and relatively modest sample size may have been insufficiently powered to detect the small intergroup effects observed (r = 0.13–0.16) for recession depth, root coverage, and complete root coverage. The inclusion of RT1/RT2 maxillary recession defects and the distinction between single- and multiple-site involvement may limit the generalizability of the outcomes to other anatomical sites. The study's observations could have been strengthened by employing volumetric soft tissue analysis to evaluate gingival thickness. Additionally, patient-reported morbidity outcomes other than pain, i.e., discomfort, swelling, analgesic consumption, willingness to undergo retreatment, and patient preferences were not documented limiting the ability to evaluate and compare the postoperative morbidity between groups. The strengths of this randomized prospective study are demonstrated by its adherence to CONSORT reporting guidelines and the inclusion of both patient-perceived esthetic outcomes and clinician reported outcome measures, which permitted comprehensive evaluation of treatment efficacies. The 12-month follow-up period allowed for the assessment of the stability of clinical outcomes over time. The comparison with the well-established de-epithelialized free gingival graft (DFGG), control intervention, increased the clinical relevance of the findings. The validity and reliability of the results could be further enhanced by implementing a split-mouth study design, stratifying patients based on recession type (isolated or multiple), and incorporating larger cohorts with extended post-operative follow-up. Conclusion Within the constraints of this study, no statistically significant differences in clinical outcomes were identified between i-PRF-enriched VCMX and DFGG for the treatment of maxillary gingival recession defects. Patient's consent Written informed consent was obtained from all the patients for participation in the study and publication of the case details and images. Ethical clearance This clinical trial was approved by the Institutional Ethics Committee and Scientific Review Board of SRM Dental College (SRMDC/IRB/2022/MDS/No.504). Clinical trial registry The study was registered with the Clinical Trials Registry of India (CTRI/2023/08/056045). Human rights statement All procedures performed in this study involving human participants were in accordance with the ethical principles outlined in the revised Declaration of Helsinki 2013 and received approval from the Institutional Ethics Committee (SRMDC/IRB/2022/MDS/No.504). Authors’ contribution Dr. Sanathana Polimera and Dr. Anupama Tadepalli conceptualized the study design. Dr. Anupama Tadepalli performed all surgical procedures. Dr. Sanathana Polimera evaluated the clinical parameters at all time points and drafted the manuscript. Dr. Harinath Parthasarathy interpreted research outcomes and drafted the results. Dr. Priyanka Cholan and Dr. Lakshmi Ramachandran revised the manuscript. All authors approved the final version of the article and agreed to be accountable for all aspects of the work in ensuring the questions related to the accuracy and integrity of any part of the work. Data availability De-identified data supporting the findings of this study are available from the corresponding author upon request. Human statement •This prospective, randomized, parallel-arm clinical trial was registered with the Clinical Trials Registry–India (CTRI/2023/08/056045) and approved by the Institutional Ethics Committee and Scientific Review Board of SRM Dental College (SRMDC/IRB/2022/MDS/No.504).•The protocol adhered CONSORT guidelines and complied with the ethical principles outlined in the revised Declaration of Helsinki (2013).•Individuals fulfilling the research criteria were informed about the study's intent and purpose, the details of the interventions, and the associated possible complications. Volunteers were then included after procuring written informed consent forms prior to enrolment. •This prospective, randomized, parallel-arm clinical trial was registered with the Clinical Trials Registry–India (CTRI/2023/08/056045) and approved by the Institutional Ethics Committee and Scientific Review Board of SRM Dental College (SRMDC/IRB/2022/MDS/No.504). This prospective, randomized, parallel-arm clinical trial was registered with the Clinical Trials Registry–India (CTRI/2023/08/056045) and approved by the Institutional Ethics Committee and Scientific Review Board of SRM Dental College (SRMDC/IRB/2022/MDS/No.504). •The protocol adhered CONSORT guidelines and complied with the ethical principles outlined in the revised Declaration of Helsinki (2013). The protocol adhered CONSORT guidelines and complied with the ethical principles outlined in the revised Declaration of Helsinki (2013). •Individuals fulfilling the research criteria were informed about the study's intent and purpose, the details of the interventions, and the associated possible complications. Volunteers were then included after procuring written informed consent forms prior to enrolment. Individuals fulfilling the research criteria were informed about the study's intent and purpose, the details of the interventions, and the associated possible complications. Volunteers were then included after procuring written informed consent forms prior to enrolment. Sources of funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.